Potter, DJ; Hammond, K; Tuffnell, S; Walker, C; Forti, MD. Potency of Δ9-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology Drug Test. Anal., 1 Apr 2018, 10 (4), 628–635. 470 kB. https://doi.org/10.1002/dta.2368
Shulgin, AT. Chemistry of psychotomimetics In Handbook of Experimental Pharmacology. Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs; Hoffmeister, F; Stille, G, Eds., Springer-Verlag, Berlin, 1 Jan 1982; Vol. 55 (3), pp 3–29. 928 kB. https://doi.org/10.1007/978-3-642-67770-0_1 #20c
Shulgin, AT. Hallucinogens In Burger’s Medicinal Chemistry, 4th ed., Part III; Wolff, ME, Ed., John Wiley & Sons, Inc., 1 Jan 1981; pp 1109–1137. 4.7 MB. #55
Shulgin, AT. Psychotomimetic agents In Psychopharmacological Agents; Gordon, M, Ed., Academic Press, New York, 1 Jan 1976; Vol. 4, pp 59–146. 3.1 MB. #LXXXVII
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #3
Russo, EB; Marcu, J. Cannabis pharmacology: The usual suspects and a few promising leads In Adv. Pharmacol.; , Elsevier, 1 Jan 2017; pp 67–134. 1.6 MB. https://doi.org/10.1016/bs.apha.2017.03.004 #Cannabinol
Meyers-Riggs, B. Phytocannabinoids countyourculture, countyourculture: rational exploration of the underground, 26 Oct 2010. #CBN
Banister, SD; Arnold, JC; Connor, M; Glass, M; McGregor, IS. Dark classics in chemical neuroscience: Δ9-Tetrahydrocannabinol ACS Chem. Neurosci., 15 May 2019, 10 (5), 2160–2175. 1.8 MB. https://doi.org/10.1021/acschemneuro.8b00651 #6a
Brimblecombe, RW; Pinder, RM. Hallucinogenic agents, Wright-Scientechnica, Bristol, UK, 1 Jan 1975. 46.2 MB. #5.1
Shulgin, AT. Recent developments in cannabis chemistry J. Psychoactive Drugs, 1 Oct 1968, 2 (1), 15–29. 1.3 MB. https://doi.org/10.1080/02791072.1968.10524397 #I
Shulgin, AT. Chemistry and structure-activity relationships of the psychotomimetics In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1 Jan 1970; pp 21–41. 8.6 MB. #Cannabinol
Bailey, K; Gagné, DR. Distinction of synthetic cannabidiol, cannabichromene, and cannabivarin by GLC using on-column methylation J. Pharm. Sci., 1 Oct 1975, 64 (10), 1719–1720. 169 kB. https://doi.org/10.1002/jps.2600641033 #VII GC,MS
Rhee, M; Vogel, Z; Barg, J; Bayewitch, M; Levy, R; Hanuš, L; Breuer, A; Mechoulam, R. Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibition of Adenylylcyclase J. Med. Chem., 1 Sep 1997, 40 (20), 3228–3233. 273 kB. https://doi.org/10.1021/jm970126f #1a NMR,IR